July 2018 Vol. 6 No.7

Abstract
• Full text
•Reprint (PDF) (65 KB)

Search Pubmed for articles by:
 

Original Research Article

Hypercholesterolemia Detection of Public Health Camp to Prevent Cardiovascular Risk – An Experience in Iraq

Saurav Deka^1*, Siddhesh Sharma¹, Nitin Shelar², Onkar Kulkarni² and Abhijit Sonowal²

¹Department of Medical and Clinical Research, Ajanta Pharmaceutical, Mumbai, India
²Global Marketing and Strategy Research, Ajanta Pharmaceutical, Mumbai, India

*Corresponding Author Email: hisaurav2000@yahoo.co.in
Mobile: +917600526455

Accepted July 02, 2018

Abstract

Hypercholesterolemia is a major risk factors for the cardiovascular disease leading to morbidity and mortality. In last 30 years, Middle East has seen dramatic and significant changes in terms of economic development and their diet and life style, which leads to disarrangements in lipid profile. Lipid profile consists of group of biochemical tests (total cholesterol, triglycerides, high density lipoprotein and low density lipoprotein) often used in predicting and treating lipid related disorders specially atherosclerosis. Due to lack of awareness in people, high cholesterol becomes a major risk factor for the cardiovascular death. Public awareness is one of the successful tools to prevent such premature death. Total 20 cholesterol camps held in different hospitals and doctor’s clinics which includes12 in Baghdad, 3 in Najaf, and 2 in Erbil, Karbala and Hilaa and 1 in Diwania. Volunteers included both patients and their attendants present in the hospital premises for different reasons. Total 577 individual participated in cholesterol detection camps. Out of which 424 males and 153 females. 12% volunteers had total cholesterol level under 149 mg/dl, 24% had in between 150 and 179 mg/dl, 31% volunteers had in between 180 and 199 mg/dl, 25% volunteers had in between 200 and 249 mg/dl and 8% had above 250 mg /dl. So, out of total 577 patients, 33% patient had cholesterol level more than 200 mg/dl. 5% prescription of atorvastatin (ATORFIT) prescribed by Physician where cholesterol level in between 180 to 199. 8% prescription of atorvastatin (ATORFIT) prescribed by Physician where cholesterol level in between 200 to 249. 8% prescription of atorvastatin (ATORFIT) prescribed by Physician where cholesterol level above 250mg/dl.

Keywords: Hypercholesterolemia, cardiovascular disease, Morbidity, Mortality